autodesk inventor lt 2015 prices buy indesign cs4 for macs purchase microsoft office 2013 download adobe photoshop lightroom purchase cheapest office 2013 professional buy adobe framemaker 9.0 buy rosetta stone chinese cheap cheap acronis true image 11 buying screenflow for mac buy rosetta stone spanish used cheap adobe dreamweaver cc 2014 mac buy visio 2010 buy adobe acrobat professional 6 buy 2010 office online buy office outlook 2003
buy autocad lt 2010 uk buy elements 8 photoshop best price adobe photoshop elements 8 cheap adobe cs2 price of adobe incopy cc 2014 buy excel by itself buy microsoft office ultimate discount adobe photoshop cs6 buy windows server 2003 software cheap microsoft office 2013 home and business buy adobe lightroom singapore price of adobe dreamweaver cc 2014 nero multimedia suite 10 price adobe elearning suite cheap buy adobe captivate 4

The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review

Wed, Sep 4, 2013

Oral Cancer News

Source: jnm.snmjournals.org
Authors: Kamal Patel et al

PET and PET/CT are widely used for surveillance of patients after cancer treatments. We conducted a systematic review to assess the diagnostic accuracy and clinical impact of PET and PET/CT used for surveillance in several cancers.

Methods: We searched MEDLINE and Cochrane Library databases from 1996 to March 2012 for English-language studies of PET or PET/CT used for surveillance of patients with lymphoma, colorectal cancer, or head and neck cancer. We included prospective or retrospective studies that reported test accuracy and comparative studies that assessed clinical impact.

Results: Twelve studies met our inclusion criteria: 6 lymphoma (n = 767 patients), 2 colorectal cancer (n = 96), and 4 head and neck cancer (n = 194). All studies lacked a uniform definition of surveillance and scan protocols. Half the studies were retrospective, and a third were rated as low quality. The majority reported sensitivities and specificities in the range of 90%–100%, although several studies reported lower results. The only randomized controlled trial, a colorectal cancer study with 65 patients in the surveillance arm, reported earlier detection of recurrences with PET and suggested improved clinical outcomes.

Conclusion: There is insufficient evidence to draw conclusions on the clinical impact of PET or PET/CT surveillance for these cancers. The lack of standard definitions for surveillance, heterogeneous scanning protocols, and inconsistencies in reporting test accuracy preclude making an informed judgment on the value of PET for this potential indication.

Authors:
Kamal Patel, Nira Hadar, Jounghee Lee, Barry A. Siegel, Bruce E. Hillner and Joseph Lau
Source: Journal of Nuclear Medicine September 1, 2013 vol. 54 no. 9 1518-1527

Print Friendly
Be Sociable, Share!
, , , ,

Leave a Reply

You must be logged in to post a comment.